X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

MTCR

Closed

Metacrine inc

0.5814
-0.0076 (-1.29%)
Last Update: 20 Jun 2023 22:11:00
Yesterday: 0.589
Day's Range: 0. - 0.
Send
When Written:
 
0.565
Metacrine Inc is a biotech company that focuses on developing drugs for metabolic diseases. The company was founded in 2015 and is headquartered in San Diego, California. Metacrine's lead drug candidate, MET409, is a small molecule agonist of the farnesoid X receptor (FXR) that is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases. MET409 is currently in Phase 2 clinical trials. Metacrine also has a pipeline of other FXR agonists for the treatment of NASH and other metabolic diseases. The company has partnerships with Novo Nordisk and Gilead Sciences for the development of its FXR agonists.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X